Suppr超能文献

表面活性蛋白 D 作为小儿镰状细胞病患者肺部并发症的标志物:与肺功能测试的关系。

Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests.

机构信息

Faculty of Medicine, Pediatrics Department, Ain Shams University, Cairo, Egypt.

Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

出版信息

Pediatr Pulmonol. 2019 May;54(5):610-619. doi: 10.1002/ppul.24257. Epub 2019 Jan 22.

Abstract

BACKGROUND

Surfactant protein D (SP-D) is considered a candidate biomarker for lung integrity and for disease progression.

AIM

We determined the level of SP-D in children and adolescents with SCD and assessed its possible relation to pulmonary complications and lung function.

METHODS

Serum SP-D levels were assessed in 50 SCD patients compared with 30 healthy controls. High-resolution computerized tomography (HRCT) of the chest was done. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV ), FEV /FVC% and forced expiratory flow rate during 25-75% of expiration (FEF25-75%) were determined.

RESULTS

SP-D was significantly higher in SCD patients than controls, particularly patients with sickle cell anemia than those with sickle β-thalassemia. SP-D levels were significantly associated with increasing severity of interstitial lung disease. The highest SP-D levels were observed among patients with restrictive lung disease followed by mixed type then obstructive lung disease. SP-D was positively correlated to HbS and serum ferritin while negatively correlated to duration of hydroxyurea treatment and parameters of pulmonary functions. ROC curve analysis revealed that SP-D cutoff value 720 ng/mL could significantly detect the presence of abnormal pulmonary function among SCD patients with 82% sensitivity and 88% specificity. Logistic regression analysis showed that SP-D is an independent factor related to abnormal pulmonary function in SCD.

CONCLUSIONS

SP-D may be a promising biomarker for screening of SCD patients for risk of later pulmonary complications.

摘要

背景

表面活性蛋白 D(SP-D)被认为是肺完整性和疾病进展的候选生物标志物。

目的

我们测定了 SCD 患儿和青少年的 SP-D 水平,并评估其与肺部并发症和肺功能的可能关系。

方法

将 50 例 SCD 患者与 30 例健康对照者进行比较,评估血清 SP-D 水平。行胸部高分辨率计算机断层扫描(HRCT)。测定用力肺活量(FVC)、第 1 秒用力呼气量(FEV )、FEV/FVC%和 25%-75%呼气流速(FEF25-75%)。

结果

SCD 患者的 SP-D 明显高于对照组,尤其是镰状细胞贫血患者高于镰状细胞β-地中海贫血患者。SP-D 水平与间质性肺病严重程度呈显著正相关。在限制性肺疾病患者中观察到最高的 SP-D 水平,其次是混合性然后是阻塞性肺疾病。SP-D 与 HbS 和血清铁蛋白呈正相关,与羟基脲治疗时间和肺功能参数呈负相关。ROC 曲线分析显示,SP-D 截断值 720ng/ml 可显著检测出 SCD 患者异常肺功能的存在,其敏感性为 82%,特异性为 88%。Logistic 回归分析显示,SP-D 是 SCD 患者异常肺功能的独立相关因素。

结论

SP-D 可能是筛查 SCD 患者发生肺部并发症风险的有前途的生物标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验